Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: BadMan who wrote (3598)	1/13/1998 1:32:00 PM
From: JOHN W.	Read Replies (1) \| Respond to of 6136

Subject: Second quarter report and conference call Date: Tue, Jan 13, 1998 00:24 EST From: LMoss Message-id: <19980113052400.AAA04582@ladder01.news.aol.com> Agouron reported 2Q earnings today, and followed up with a conference call. I'll summarize some of the points I think are particularly significant. After-tax earnings, fully diluted, were reported as $.15/share. (Because of NOL carry-forwards, Agouron does not currently pay any tax; under the old reporting system, it would have reported $.25/share.) (Note also that Agouron spends about $1/share each quarter on R&D, which, according to accounting rules, is reported as an operating expense, but which can also be viewed as an investment in future products.) Total revenues were $104.7 million. Viracept revenues were $91.8 million, of which $84.5 million were U.S. sales, an increase of 12% over the previous quarter. Viracept now accounts for 36% of the revenues for all PIs in the U.S. and leads the field in that respect. It will be tough for any future PI competitor to match, much less exceed, in that it has unsurpassed potency, tolerability, safety profile, and ease of use (and BID dosing studies look quite favorable). Agouron estimates that U.S. sales of Viracept in FY98 will be in the range of $350 to $360 million. I think this may be conservative if the acceleration in growth I previously estimated would take place beginning in late 3QF98 indeed occurs. This delay in growth is, I believe, a natural consequence of delays in the system: Informing health care providers of the superiority of Viracept, with clinical data to back this up; the three to four month interval between viral load tests recommended in the guidelines before starting most asymptomatic HIV patients on antiretroviral therapy; and delays in making money available for therapy. Despite all this, the Viracept launch to date is the most successful in the history of the biotechnology industry, surpassing the launch of Amgen's Epogen. Viracept gross margins on U.S. sales were 63% in the quarter. Agouron expects an increase to about 68 to 69% by the end of the year, with an average for the (fiscal) year of 64%. Cash and cash equivalents increased to $117 million. EU approval of Viracept is expected later this quarter. By the end of the fiscal year, approval in Japan, Brazil, Canada, and New Zealand is expected. Agouron estimates that currently 8 to 13% of patients are now receiving 2PI combination therapy. These are mostly people who have experienced failure with initial therapy. Agouron estimates that over the next year 20 to 25% of patients will be on 2PI combination therapy, with a greater proportion of them using it for initial therapy. There will be at least 15 papers presented at the Chicago meeting starting Feb. 1 relating to Viracept. Favorable results on BID dosing will be presented, but an even larger sample size will be needed to satisfy new FDA criteria before submitting an application for a label change (estimated by the end of the calendar year). (Note that a label change is not required for health care providers to use BID, but it is necessary if Agouron is to promote this change.) A long-term followup of Study 511 will be presented, using an ultrasensitive assay, showing unsurpassed potency. Data on various PI combinations will be presented. I expect the data on some of the Viracept combinations to be very positive. Data on resistance and cross-resistance will be presented. I expect this to be favorable to Viracept, but final proof of its superiority in this respect will take longer to demonstrate to statistical satisfaction. With respect to other drugs, AG3340, the MMP inhibitor for cancer, is expected to advance to Phase ll/lll trials later this quarter. This is most encouraging, as it has the potential to be another blockbuster drug. A rhinovirus PI candidate should be identified and enter clinical trials by the end of the calendar year. The GART inhibitor for cancer is currently in dose-ranging studies. (A key issue for any GART inhibitor is the avoidance of cumulative toxicity, and studies to determine this must be done with great care.) While I think of it, there has been speculation on some of these boards that Agouron might develop a successor PI to Viracept. I think this most unlikely, because Viracept is such a good PI. More likely is the development of an integrase inhibitor which can attack HIV DNA in resting T-cells. I would not be surprised if in two to three years Agouron developed, tested, and submitted for approval such an inhibitor. In summary, it was a good quarter, and the best is yet to come. LMoss

To: BadMan who wrote (3598)	1/13/1998 1:51:00 PM
From: JOHN W.	Read Replies (1) \| Respond to of 6136

Monday January 12, 8:04 am Eastern Time Company Press Release HIV Therapies: Paradox in Drug Promotion? NEWTOWN, Pa.--(BW HealthWire)--Jan. 12, 1998--The unique status of AIDS has led to a seeming paradox in the way pharmaceutical manufacturers market HIV therapies to managed care organizations, according to the latest analysis from the health care consulting firm Scott-Levin. ''Almost all HIV therapies are on managed care formularies, or lists of approved drugs,'' said Joy Scott, chief executive officer of Scott-Levin. But this is happening despite low promotion of the drugs by their manufacturers. Promotion of HIV treatments to managed care has declined 74 percent since spring 1996, when many of the newer-generation HIV drugs were being launched. The reason is that many managed care companies leave HIV therapy decisions to individual physicians because HMOs don't yet have guidelines for treating the disease. HMOs and other managed care organizations are sensitive to potential criticism about withholding lifesaving therapy. One pharmacy executive at a leading managed care organization explained: ''Treatment of HlV has traditionally been customized to the patients. Until recently, there was no clearly defined 'best therapy.''' However, in July 1997, the U.S. government released HIV treatment guidelines intended to standardize and improve the quality of care for patients. These guidelines recommend treating HIV early with an aggressive triple drug regimen consisting of a combination of two nucleotide inhibitors and one protease inhibitor. There are currently four protease inhibitors on the market for HIV: Merck's Crixivan, Abbott's Norvir, Roche's Invirase and the latest entry, Agouron's Viracept. The nucleotide inhibitors include Glaxo Wellcome's Epivir and Retrovir, Bristol-Myers Squibb's Videx and Zerit, Roche's Hivid, Pharmacia & Upjohn's Rescriptor, and Roxane's Viramune. The most promoted HIV therapy to managed care in spring 1997 was Viracept, according to Scott-Levin's Managed Care Pharmacy Executive Promotional Audit. During this time period, Agouron account personnel focused on introducing Viracept to managed care and ensuring that it would become part of a managed care organization's benefit design. Outcomes studies were also presented. Crixivan recorded the second-highest level of promotion to managed care executives in spring 1997. Merck's sales force reviewed distribution methods and federal recommendations on occupational HIV exposure. Crixivan's formulary placement was also discussed. Results from Scott-Levin's fall 1997 Managed Care Pharmacy Executive Promotional Audit will soon be available. ''It will be interesting to see if the new HIV guidelines have had any effect on managed care promotion,'' said Scott. According to Scott-Levin's HIV Therapy Audit, 363,640 U.S. patients sought treatment for HIV in the third quarter of 1997. More than two-thirds of those patients received triple antiretroviral therapy (70 percent), followed by dual therapy (23 percent), quadruple therapy (5 percent) and single-drug therapy (2 percent). For more information, contact Kathy Carlson or Rob Houghton at 800/982-5613; email@scottlevin.com. Scott-Levin, a subsidiary of PMSI/Scott-Levin Inc., provides consulting and communications services to pharmaceutical companies worldwide.